secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alzamend Neuro, Inc. (ALZN)
CIK:        0001677077
Form:       8-K
Filed at:   2024-03-29T23:59:59+00:00
Accession:  0001214659-24-005635
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 1.01, 3.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alzamend Neuro faces Nasdaq delisting over MVLS; sells $780K Series B convertible to affiliate
--------------------------------------------------------------------------------

- Nasdaq notified ALZN it fails MVLS rule; delisting scheduled for April 4 unless appeal stays it.
- Company will appeal to Hearings Panel by April 2; Common Stock continues trading pending decision.
- Sold Series B convertible preferred stock and warrants for $780K to Ault Lending (affiliate); aggregate purchases now $2M of $6M available.
- Unregistered sale under Section 4(a)(2) exemption.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1677077/000121465924005635/0001214659-24-005635-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1677077/000121465924005635/p3292438k.htm
  HTML page:      https://secwatch.observer/filing/0001214659-24-005635

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer